We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
Read MoreHide Full Article
Biohaven (BHVN - Free Report) announced that it has acquired global license rights (excluding China regions) for BHV-8000 from Hangzhou Highlightll Pharmaceuticals for immune-mediated brain disorders.
BHV-8000 (previously TLL-041) is a highly selective, brain-penetrant, dual tyrosine kinase 2 (TYK2) and janus kinase 1 (JAK1) inhibitor.
Shares of Biohaven lost almost 6% on Mar 22 and plunged 88.6% in the past year compared with the industry’s 16.8% decline.
Image Source: Zacks Investment Research
The company plans to advance the agent into a phase I study in 2023.
With the help of the novel first-in-class dual inhibition of TYK2/JAK1, BHVN plans to target severe neurological disorders. BHV-8000 has demonstrated high selectivity over JAK2, JAK3 and other kinases, potentially offering improved safety over less selective or non-selective JAK inhibitors.
Biohaven and Highlightll will join forces for the clinical development of BHV-8000 across the world. Per the agreement, the latter will receive $10 million in upfront cash and $10 million worth of BHVN equity. It is also entitled to development and commercial milestone payments of up to $950 million and tiered royalty payments ranging from mid-single digit to lower teen percentages.
Adding the BHV-8000 candidate to BHVN’s pipeline will help grow the existing complementary neuro-immunomodulatory therapeutic approaches, including selective extracellular degraders (commonly referred to as LYTACs or MoDEs) against IgG, IgA and antigen-specific targets.
Biohavens’ under-development product candidates include Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, and myostatin inhibition for neuromuscular diseases.
Loss per share estimates for Kala Pharmaceuticals have narrowed from $19.67 to $15.35 for 2023 and from $14.41 to $13.12 for 2024 in the past 60 days. KALA’s shares have plunged 81.4% in the past year.
KALA’s earnings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 11.56%.
CRISPR Therapeutics' 2023 loss per share estimates have narrowed from $8.21 to $7.54, in the past 60 days.
CRSP's earnings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 3.19%. CRSP’s shares have plunged 31.6% in the past year.
Loss per share estimates for Jasper Therapeutics have narrowed from $1.42 to 61 cents for 2023 and from $1.6 to 59 cents for 2024, in the past 60 days. JSPR’s shares have plunged 45.2% in the past year.
JSPR’s earnings beat estimates in three of the last four quarters and met the mark in one, the average surprise being 3.51%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
Biohaven (BHVN - Free Report) announced that it has acquired global license rights (excluding China regions) for BHV-8000 from Hangzhou Highlightll Pharmaceuticals for immune-mediated brain disorders.
BHV-8000 (previously TLL-041) is a highly selective, brain-penetrant, dual tyrosine kinase 2 (TYK2) and janus kinase 1 (JAK1) inhibitor.
Shares of Biohaven lost almost 6% on Mar 22 and plunged 88.6% in the past year compared with the industry’s 16.8% decline.
Image Source: Zacks Investment Research
The company plans to advance the agent into a phase I study in 2023.
With the help of the novel first-in-class dual inhibition of TYK2/JAK1, BHVN plans to target severe neurological disorders. BHV-8000 has demonstrated high selectivity over JAK2, JAK3 and other kinases, potentially offering improved safety over less selective or non-selective JAK inhibitors.
Biohaven and Highlightll will join forces for the clinical development of BHV-8000 across the world. Per the agreement, the latter will receive $10 million in upfront cash and $10 million worth of BHVN equity. It is also entitled to development and commercial milestone payments of up to $950 million and tiered royalty payments ranging from mid-single digit to lower teen percentages.
Adding the BHV-8000 candidate to BHVN’s pipeline will help grow the existing complementary neuro-immunomodulatory therapeutic approaches, including selective extracellular degraders (commonly referred to as LYTACs or MoDEs) against IgG, IgA and antigen-specific targets.
Biohavens’ under-development product candidates include Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, and myostatin inhibition for neuromuscular diseases.
Biohaven Ltd. Price and Consensus
Biohaven Ltd. price-consensus-chart | Biohaven Ltd. Quote
Zacks Rank & Stocks to Consider
Currently, Biohaven has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same sector are Kala Pharmaceuticals (KALA - Free Report) , CRISPR Therapeutics (CRSP - Free Report) and Jasper Therapeutics (JSPR - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for Kala Pharmaceuticals have narrowed from $19.67 to $15.35 for 2023 and from $14.41 to $13.12 for 2024 in the past 60 days. KALA’s shares have plunged 81.4% in the past year.
KALA’s earnings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 11.56%.
CRISPR Therapeutics' 2023 loss per share estimates have narrowed from $8.21 to $7.54, in the past 60 days.
CRSP's earnings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 3.19%. CRSP’s shares have plunged 31.6% in the past year.
Loss per share estimates for Jasper Therapeutics have narrowed from $1.42 to 61 cents for 2023 and from $1.6 to 59 cents for 2024, in the past 60 days. JSPR’s shares have plunged 45.2% in the past year.
JSPR’s earnings beat estimates in three of the last four quarters and met the mark in one, the average surprise being 3.51%.